Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007
Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017 Year: 2017
The cost of treatment of tuberculosis in children of Belarus Source: Virtual Congress 2020 – How do different treatment strategies translate into costs Year: 2020
Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy Source: Eur Respir J 2004; 24: 11-17 Year: 2004
The effectiveness of the treatment of patients with TB in the condition adapted DOTS-strategy in Ukraine Source: Annual Congress 2008 - Outcomes of tuberculosis treatment Year: 2008
Preventive chemotherapy effectiveness in children and adolescents, contacting TB patients with DR TB strains Source: Eur Respir J 2006; 28: Suppl. 50, 536s Year: 2006
Treatment results in patients with XDR tuberculosis in Ukraine Source: Eur Respir J 2007; 30: Suppl. 51, 272s Year: 2007
The peculiarities of histological diagnostic of tuberculosis (TB) in HIV-infected patients in Ukraine Source: Eur Respir J 2006; 28: Suppl. 50, 20s Year: 2006
Should tuberculosis treatment and control be addressed differently in HIV-infected and -uninfected individuals? Source: Eur Respir J 2005; 25: 751-757 Year: 2005
High prevalence of hepatitis C among patients with drug-resistant tuberculosis and its impact on the treatment outcome in Azerbaijan prisons Source: International Congress 2015 – Screening strategies in TB Year: 2015
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
TB drug resistance in high-incidence countries Source: Eur Respir Mon 2012; 58: 95-110 Year: 2012
The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? Source: Eur Respir J, 50 (2) 1700753; 10.1183/13993003.00753-2017 Year: 2017
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Recurrent tuberculosis among HIV-infected patients in Novokuznetsk, Russia. Source: International Congress 2019 – Tuberculosis: from diagnosis to complications Year: 2019
Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa Source: Eur Respir J, 51 (5) 1800544; 10.1183/13993003.00544-2018 Year: 2018
Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia Source: Eur Respir J 2012; 40: 133-142 Year: 2012
Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012